{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83c\udf0d The Oral GLP-1 Era: From Injection to Independence","description":"\ud83d\udc8a Can weight loss achieved with injectable GLP-1 therapies be maintained using an oral agent? &amp;nbsp; The ATTAIN-MAINTAIN phase 3b trial published in Nature Medicine evaluated once-daily oral orforglipron after prior tirzepatide or semaglutide therapy. Patients maintained substantially more prior weight reduction versus placebo over 52 weeks, while preserving cardiometabolic benefits. \ud83c\udf0d\u2696\ufe0f &amp;nbsp; A fascinating glimpse into the future of scalable obesity care: oral incretin therapy may improve adherence, accessibility, and long-term maintenance. &amp;nbsp; #Obesity #GLP1 #Orforglipron #NatureMedicine #Cardiology #Endocrinology #MedicalPodcast #PhysicianEducation ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41326505\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/202051660"}